{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:12:13Z","timestamp":1770138733943,"version":"3.49.0"},"reference-count":51,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["260203"],"award-info":[{"award-number":["260203"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate the therapeutic potential of the next\u2010generation anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>37 radioimmunoconjugate <jats:sup>177<\/jats:sup>Lu\u2010lilotomab satetraxetan (<jats:sup>177<\/jats:sup>Lu\u2010lilotomab) in combination with the anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 antibody rituximab for treatment of mice with non\u2010Hodgkin's lymphoma (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>) xenografts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Nude mice with subcutaneous (s.c.) Burkitt's lymphoma Daudi xenografts and <jats:styled-content style=\"fixed-case\">SCID<\/jats:styled-content> mice intravenously (i.v.) injected with Mantle cell lymphoma Rec\u20101 cells were treated with either <jats:sup>177<\/jats:sup>Lu\u2010lilotomab or rituximab alone or with the combination of both treatments. Tumour volume, body weight, blood counts and clinical status were monitored. <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 expression was measured using flow cytometry with fluorescence\u2010labelled rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The combination of <jats:sup>177<\/jats:sup>Lu\u2010lilotomab and rituximab was synergistic for treatment of nude mice with s.c. Daudi xenografts while it was additive for treatment of <jats:styled-content style=\"fixed-case\">SCID<\/jats:styled-content> mice with i.v. injected Rec\u20101 cells. Binding of rituximab to <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> cells in\u2010vitro was increased by pretreatment with <jats:sup>177<\/jats:sup>Lu\u2010lilotomab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment of mice with <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> xenografts with <jats:sup>177<\/jats:sup>Lu\u2010lilotomab synergistically increased tumour suppression of subsequent anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 immunotherapy and improved survival. If the same effect is confirmed in a recently started clinical study, it could change the way radioimmunotherapy and <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 immunotherapy would be used in the future.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13139","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T10:55:31Z","timestamp":1531306531000},"page":"522-531","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Combination of <sup>177<\/sup>Lu\u2010lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non\u2010Hodgkin's lymphoma"],"prefix":"10.1111","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5390-0692","authenticated-orcid":false,"given":"Ada H. V.","family":"Repetto\u2010Llamazares","sequence":"first","affiliation":[{"name":"Nordic Nanovector ASA  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion M.","family":"Malenge","sequence":"additional","affiliation":[{"name":"Nordic Nanovector ASA  Oslo Norway"},{"name":"Department of Radiation Biology Institute for Cancer Research Oslo University Hospital  Oslo Norway"},{"name":"Institute of Clinical Medicine Faculty of Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"O'Shea","sequence":"additional","affiliation":[{"name":"Nordic Nanovector ASA  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bergth\u00f3ra","family":"Eir\u00edksd\u00f3ttir","sequence":"additional","affiliation":[{"name":"ArcticLAS Ltd. CRO  Reykjav\u00edk Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trond","family":"Stokke","sequence":"additional","affiliation":[{"name":"Department of Radiation Biology Institute for Cancer Research Oslo University Hospital  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy H.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Sciencons AS  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jostein","family":"Dahle","sequence":"additional","affiliation":[{"name":"Nordic Nanovector ASA  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"issue":"6","key":"e_1_2_8_3_1","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier B","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.10.005"},{"key":"e_1_2_8_6_1","unstructured":"NCCN Guidelines Non\u2010Hodgkin's Lymphomas version 3.2017."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"issue":"11","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood.V112.11.3783.3783","article-title":"The impact of rituximab resistance on overall survival rate in low\u2010grade follicular lymphoma","volume":"112","author":"Abdollahi S","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_9_1","unstructured":"BergerMJ Coursey JS ZuckerM A ChangJ.Stopping\u2010power and range tables for electrons protons and helium ions (NIST) 2009[cited 2016 July]; Available from:http:\/\/www.nist.gov\/pml\/data\/star\/"},{"issue":"1","key":"e_1_2_8_10_1","first-page":"85","article-title":"Evaluating antigen targeting and anti\u2010tumor activity of a new anti\u2010CD37 radioimmunoconjugate against non\u2010Hodgkin's lymphoma","volume":"33","author":"Dahle J","year":"2013","journal-title":"Anticancer Res"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403822"},{"issue":"3","key":"e_1_2_8_12_1","first-page":"644","article-title":"Significance of CD37 expression in malignant B cells","volume":"22","author":"Wang W","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"21","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood.V116.21.3098.3098","article-title":"CD37 Is a Potential Therapeutic Target for B\u2010Cell Non\u2010Hodgkin Lymphoma","volume":"116","author":"Zhao X","year":"2010","journal-title":"Blood"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128816"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","unstructured":"KolstadA MatsbuU DahleJ et\u00a0al.A phase I Study of177Lu\u2010DOTA\u2010HH1 (BetalutinTM) Radioimmunotherapy in Patients with Relapsed CD37\u00a0+\u00a0 Non\u2010Hodgkin B\u2010Cell Lymphoma. 56th ASH Annual Meeting San Francisco CA Dec 6\u20109 2014;2014.","DOI":"10.1182\/blood.V124.21.3094.3094"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.79"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2007.10.048"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1018"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.157"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1429"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717693574"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90435-6"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(86)21067-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/347479a0"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103070"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1685"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-160747"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1905"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2795"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2352"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.195925"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13318"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.12040"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1085137"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/61\/19\/6935"},{"issue":"2","key":"e_1_2_8_36_1","first-page":"86","article-title":"Advances and application of radioimmunotherapy in non\u2010Hodgkin lymphoma","volume":"2","author":"Stevens PL","year":"2012","journal-title":"Am J Blood Res"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011306010004"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.04.052"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.06.001"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.6338"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0073"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1001074107"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.567262"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.5581\/1516-8484.20110036"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03843.x"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.56.89"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1304"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-133108"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-244129"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:21:29Z","timestamp":1728480089000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/ejh.13139"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13139","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"2018-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}